Tedatioxetine (previously known as Lu AA24530) is a multimodal antidepressant that was developed for the treatment of depression and anxiety disorders (generalized anxiety disorder mainly). Tedatioxetine is a monoamine enhancer with reuptake inhibition at monoamine transporters and possesses an antagonist activity at 5-HT3 and 5-HT2c receptors. In 2009, the drug was studied in phase II clinical trials where it showed positive results in major depressive disorder. However, it remains unclear as to whether tedatioxetine development has been postponed and/or abandoned.